Genetic predictors of insulin-producing pancreatic tumor

Cover Page


Cite item

Full Text

Abstract

Insulinoma is the most common functioning tumor of the pancreas. Approximately 5% of its cases are associated with the multiple endocrine neoplasia syndrome type 1 (MEN1), caused by mutation in the MEN1 gene. MEN1 can be manifested by pituitary and parathyroid adenomas, pancreatic neuroendocrine tumors, tumors of the thyroid gland, adrenals, intestine, carcinoids of lungs and other organs. However, in 5–10% of the patients with clinical manifestation of this syndrome, MEN1 mutations cannot be identified. Moreover, the disease can be caused by various abnormalities (mutations, polymorphisms, etc.) in other genes. More than 30 genes, associated with insulin-producing pancreatic tumors, have been described in the literature. With a known germinal mutation, the prognosis and management of patients with insulinoma can be determined by the hereditary disease with which the tumor is associated. The article emphasizes the need to search for new genetic markers that predispose to the development of insulinoma. The necessity of extended genetic testing of patients with insulinomas is discussed, primarily of young patients with multifocal lesions, family history and associated disorders.

About the authors

M. Yu. Yukina

National Medical Research Center of Endocrinology

Author for correspondence.
Email: kuronova@yandex.ru

Marina Yu. Yukina - MD, PhD, Leading Research Fellow, Department of Therapeutic Endocrinology,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Россия

N. F. Nuralieva

National Medical Research Center of Endocrinology

Email: fake@neicon.ru

Nurana F. Nuralieva – Research Fellow, Department of Therapeutic Endocrinology,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Россия

E. A. Troshina

National Medical Research Center of Endocrinology

Email: fake@neicon.ru

Ekaterina A. Troshina – MD, PhD, Professor, Member-Correspondent of Russian Academy of Sciences, Head of Department of Therapeutic Endocrinology,

11 Dmitriya Ul'yanova ul., Moscow, 117036

Россия

References

  1. Jensen RT, Cadiot G, Brandi ML, de Herder WW, Kaltsas G, Komminoth P, Scoazec JY, Salazar R, Sauvanet A, Kianmanesh R; Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with digestive neuroendocrine neoplasms: functional pancreatic endocrine tumor syndromes. Neuroendocrinology. 2012;95(2): 98–119. doi: 10.1159/000335591.
  2. Druce MR, Muthuppalaniappan VM, O'Leary B, Chew SL, Drake WM, Monson JP, Akker SA, Besser M, Sahdev A, Rockall A, Vyas S, Bhattacharya S, Matson M, Berney D, Reznek RH, Grossman AB. Diagnosis and localisation of insulinoma: the value of modern magnetic resonance imaging in conjunction with calcium stimulation catheterisation. Eur J Endocrinol. 2010;162(5):971–8. doi: 10.1530/EJE-10-0056.
  3. Jyotsna VP, Malik E, Birla S, Sharma A. Novel MEN 1 gene findings in rare sporadic insulinoma – a case control study. BMC Endocr Disord. 2015;15:44. doi: 10.1186/s12902-015-0041-2.
  4. Borson-Chazot F, Cardot-Bauters C, Mirallie É, Pattou F; French Endocrine Society. Insulinoma of genetic aetiology. Ann Endocrinol (Paris). 2013;74(3):200–2. doi: 10.1016/j.ando.2013.05.006.
  5. Sakurai A, Yamazaki M, Suzuki S, Fukushima T, Imai T, Kikumori T, Okamoto T, Horiuchi K, Uchino S, Kosugi S, Yamada M, Komoto I, Hanazaki K, Itoh M, Kondo T, Mihara M, Imamura M. Clinical features of insulinoma in patients with multiple endocrine neoplasia type 1: analysis of the database of the MEN Consortium of Japan. Endocr J. 2012;59(10):859–66. doi: 10.1507/endocrj.EJ12-0173.
  6. Kwon EB, Jeong HR, Shim YS, Lee HS, Hwang JS. Multiple endocrine neoplasia type 1 presenting as hypoglycemia due to insulinoma. J Korean Med Sci. 2016;31(6):1003–6. doi: 10.3346/jkms.2016.31.6.1003.
  7. Akhtar Y, Verardo A, Crane JL. Multiple endocrine neoplasia type 1 presenting with concurrent insulinoma and prolactinoma in early-adolescence. Int J Pediatr Endocrinol. 2018;2018:7. doi: 10.1186/s13633-018-0061-6.
  8. Fabbri HC, Mello MP, Soardi FC, Esquiaveto-Aun AM, Oliveira DM, Denardi FC, Moura-Neto A, Garmes HM, Baptista MT, Matos PS, Lemos-Marini SH, D'Souza-Li LF, Guerra-Júnior G. Long-term follow-up of an 8-year-old boy with insulinoma as the first manifestation of a familial form of multiple endocrine neoplasia type 1. Arq Bras Endocrinol Metabol. 2010;54(8):754–60. doi: 10.1590/S0004-27302010000800016.
  9. Goudet P, Dalac A, Le Bras M, Cardot-Bauters C, Niccoli P, Lévy-Bohbot N, du Boullay H, Bertagna X, Ruszniewski P, Borson-Chazot F, Vergès B, Sadoul JL, Ménégaux F, Tabarin A, Kühn JM, d'Anella P, Chabre O, Christin-Maitre S, Cadiot G, Binquet C, Delemer B. MEN1 disease occurring before 21 years old: a 160-patient cohort study from the Groupe d'étude des Tumeurs Endocrines. J Clin Endocrinol Metab. 2015;100(4):1568–77. doi: 10.1210/jc.2014- 3659.
  10. Vezzosi D, Cardot-Bauters C, Bouscaren N, Lebras M, Bertholon-Grégoire M, Niccoli P, LevyBohbot N, Groussin L, Bouchard P, Tabarin A, Chanson P, Lecomte P, Guilhem I, Carrere N, Mirallié E, Pattou F, Peix JL, Goere D, Borson-Chazot F, Caron P, Bongard V, Carnaille B, Goudet P, Baudin E. Long-term results of the surgical management of insulinoma patients with MEN1: a Groupe d'étude des Tumeurs Endocrines (GTE) retrospective study. Eur J Endocrinol. 2015;172(3):309–19. doi: 10.1530/EJE-14-0878.
  11. Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer. 2008;113(7 Suppl):1807–43. doi: 10.1002/cncr.23648.
  12. Lee M, Pellegata NS. Multiple endocrine neoplasia type 4. Front Horm Res. 2013;41:63–78. doi: 10.1159/000345670.
  13. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1) and type 4 (MEN4). Mol Cell Endocrinol. 2014;386(1–2):2–15. doi: 10.1016/j.mce.2013.08.002.
  14. Şimşir IY, Ertan Y, Sözbilen M, Makay Ö, Erdoğan M, Çetinkalp Ş, Saygılı LF, Yılmaz C, Berdeli A, Özgen AG. Multiple endocrine neoplasia type 4 (MEN4) syndrome. J Clin Res Pediatr Endocrinol. 2015;7 Suppl 2:77–92.
  15. Pardi E, Borsari S, Saponaro F, Bogazzi F, Urbani C, Mariotti S, Pigliaru F, Satta C, Pani F, Materazzi G, Miccoli P, Grantaliano L, Marcocci C, Cetani F. Mutational and large deletion study of genes implicated in hereditary forms of primary hyperparathyroidism and correlation with clinical features. PLoS One. 2017;12(10):e0186485. doi: 10.1371/journal. pone.0186485.
  16. Falchetti A, Brandi ML. Multiple endocrine neoplasia type I variants and phenocopies: more than a nosological issue? J Clin Endocrinol Metab. 2009;94(5):1518–20. doi: 10.1210/jc.2009- 0494.
  17. Ono Y, Oda N, Ishihara S, Shimomura A, Hayakawa N, Suzuki A, Horiguchi A, Senda T, Miyakawa S, Itoh M. Insulinoma cell calcium-sensing receptor influences insulin secretion in a case with concurrent familial hypocalciuric hypercalcemia and malignant metastatic insulinoma. Eur J Endocrinol. 2008;159(1):81–6. doi: 10.1530/EJE-08-0069.
  18. Zhou W, Gong L, Li X, Wan Y, Wang X, Li H, Jiang B. Screening key candidate genes and pathways involved in insulinoma by microarray analysis. Medicine (Baltimore). 2018;97(22):e10826. doi: 10.1097/MD.0000000000010826.
  19. Afzal M, Kathuria P. Familial hypocalciuric hypercalcemia (FHH). StatPearls [Internet]. StatPearls Publishing; 2018. Available from: https:// www.ncbi.nlm.nih.gov/books/NBK459190/.
  20. McAuley G, Delaney H, Colville J, Lyburn I, Worsley D, Govender P, Torreggiani WC. Multimodality preoperative imaging of pancreatic insulinomas. Clin Radiol. 2005;60(10):1039–50. doi: 10.1016/j.crad.2005.06.005.
  21. Vezzosi D, Bennet A, Maiza JC, Buffet A, Grunenwald S, Fauvel J, Courbon F, Otal P, Carrere N, Caron Ph. Diagnosis and treatment of insulinomas in the adults. In: Fulya A, editor. Basic and Clinical Endocrinology Up-to-Date. InTech; 2011. P. 135–76. doi: 10.5772/17452.
  22. Jonkers YMH. Molecular alterations during insulinoma tumorigenesis. Maastricht: Universiteit Maastricht; 2007. 128 p.
  23. Gillam MP, Nimbalkar D, Sun L, Christov K, Ray D, Kaldis P, Liu X, Kiyokawa H. MEN1 tumorigenesis in the pituitary and pancreatic islet requires Cdk4 but not Cdk2. Oncogene. 2015;34(7):932–8. doi: 10.1038/onc.2014.3.
  24. Wang H, Bender A, Wang P, Karakose E, Inabnet WB, Libutti SK, Arnold A, Lambertini L, Stang M, Chen H, Kasai Y, Mahajan M, Kinoshita Y, Fernandez-Ranvier G, Becker TC, Takane KK, Walker LA, Saul S, Chen R, Scott DK, Ferrer J, Antipin Y, Donovan M, Uzilov AV, Reva B, Schadt EE, Losic B, Argmann C, Stewart AF. Insights into beta cell regeneration for diabetes via integration of molecular landscapes in human insulinomas. Nat Commun. 2017;8(1):767. doi: 10.1038/s41467-017- 00992-9.
  25. Lubomierski N, Kersting M, Bert T, Muench K, Wulbrand U, Schuermann M, Bartsch D, Simon B. Tumor suppressor genes in the 9p21 gene cluster are selective targets of inactivation in neuroendocrine gastroenteropancreatic tumors. Cancer Res. 2001;61(15): 5905–10.
  26. Bartsch DK, Kersting M, Wild A, Ramaswamy A, Gerdes B, Schuermann M, Simon B, Rothmund M. Low frequency of p16(INK4a) alterations in insulinomas. Digestion. 2000;62(2–3): 171–7. doi: 10.1159/000007810.
  27. Irshad K, Jyotsna VP, Agarwal S, Chosdol K, Pal S, Deepak RK. T372R mutation status in Yin Yang 1 gene in insulinoma patients. Horm Metab Res. 2017;49(6):452–6. doi: 10.1055/s0043-107244.
  28. Cao Y, Gao Z, Li L, Jiang X, Shan A, Cai J, Peng Y, Li Y, Jiang X, Huang X, Wang J, Wei Q, Qin G, Zhao J, Jin X, Liu L, Li Y, Wang W, Wang J, Ning G. Whole exome sequencing of insulinoma reveals recurrent T372R mutations in YY1. Nat Commun. 2013;4:2810. doi: 10.1038/ncomms3810.
  29. Cromer MK, Choi M, Nelson-Williams C, Fonseca AL, Kunstman JW, Korah RM, Overton JD, Mane S, Kenney B, Malchoff CD, Stalberg P, Akerström G, Westin G, Hellman P, Carling T, Björklund P, Lifton RP. Neomorphic effects of recurrent somatic mutations in Yin Yang 1 in insulin-producing adenomas. Proc Natl Acad Sci U S A. 2015;112(13):4062–7. doi: 10.1073/pnas.1503696112.
  30. Lichtenauer UD, Di Dalmazi G, Slater EP, Wieland T, Kuebart A, Schmittfull A, Schwarzmayr T, Diener S, Wiese D, Thasler WE, Reincke M, Meitinger T, Schott M, Fassnacht M, Bartsch DK, Strom TM, Beuschlein F. Frequency and clinical correlates of somatic Ying Yang 1 mutations in sporadic insulinomas. J Clin Endocrinol Metab. 2015;100(5):E776–82. doi: 10.1210/jc.2015-1100.
  31. Baudin E, Caron P, Lombard-Bohas C, Tabarin A, Mitry E, Reznick Y, Taieb D, Pattou F, Goudet P, Vezzosi D, Scoazec JY, Cadiot G, Borson-Chazot F, Do Cao C; Société française d’endocrinologie; Groupe d’étude des tumeurs endocrines. Malignant insulinoma: recommendations for characterisation and treatment. Ann Endocrinol (Paris). 2013;74(5–6): 523–33. doi: 10.1016/j.ando.2013.07.001.
  32. Karpathakis A, Dibra H, Thirlwell C. Neuroendocrine tumours: cracking the epigenetic code. Endocr Relat Cancer. 2013;20(3):R65–82. doi: 10.1530/ERC-12-0338.
  33. Dejeux E, Olaso R, Dousset B, Audebourg A, Gut IG, Terris B, Tost J. Hypermethylation of the IGF2 differentially methylated region 2 is a specific event in insulinomas leading to loss-of-imprinting and overexpression. Endocr Relat Cancer. 2009;16(3):939–52. doi: 10.1677/ERC-08-0331.
  34. Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab. 2007;21(1):1–14. doi: 10.1016/j.beem.2006.12.001.
  35. Hrasćan R, Pećina-Slaus N, Martić TN, Colić JF, Gall-Troselj K, Pavelić K, Karapandza N. Analysis of selected genes in neuroendocrine tumours: insulinomas and phaeochromocytomas. J Neuroendocrinol. 2008;20(8):1015–22. doi: 10.1111/j.1365-2826.2008.01755.x.
  36. Johannessen LE, Panagopoulos I, Haugvik SP, Gladhaug IP, Heim S, Micci F. Upregulation of INS-IGF2 read-through expression and identification of a novel INS-IGF2 splice variant in insulinomas. Oncol Rep. 2016;36(5): 2653–62. doi: 10.3892/or.2016.5132.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Yukina M.Y., Nuralieva N.F., Troshina E.A.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies